Get the Stockscreener App
0.489
4.79%
0.0218
Alx Oncology Holdings Inc stock is traded at $0.489, with a volume of 255.13K.
It is up +4.79% in the last 24 hours and down -9.33% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$0.4672
Open:
$0.4825
24h Volume:
255.13K
Relative Volume:
0.34
Market Cap:
$26.13M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.1646
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
+5.59%
1M Performance:
-9.33%
6M Performance:
-66.92%
1Y Performance:
-95.40%
1-Day Range:
$0.4627
$0.4981
1-Week Range:
$0.4311
$0.4981
52-Week Range:
$0.4051
$11.08
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.489 | 25.59M | 0 | -151.16M | -130.08M | -2.97 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.52 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.52 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.95 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News - GuruFocus
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
ALX Oncology Management to Showcase Novel Cancer Treatment Advances at Major Jefferies Healthcare Conference - Stock Titan
D. E. Shaw & Co. Inc. Decreases Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
H.C. Wainwright maintains ALX Oncology stock Buy rating - Investing.com
H.C. Wainwright maintains ALX Oncology stock Buy rating By Investing.com - Investing.com UK
UBS Group Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Sto - GuruFocus
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Stock News - GuruFocus
UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating - marketscreener.com
ALX Oncology presents preclinical data, plans for ALX-2004 - BioWorld MedTech
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO St - GuruFocus
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO Stock News - GuruFocus
Transcript : ALX Oncology Holdings Inc.Special Call - marketscreener.com
ALX Oncology : Investor Presentation ALX2004 Webcast May 20 2025 Final (2a4ce1) - marketscreener.com
ALX Oncology Holdings Inc. Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - marketscreener.com
ALXO Unveils Advanced Antibody-Drug Conjugate ALX2004 for Tumor Treatment | ALXO Stock News - GuruFocus
ALX Oncology Highlights Differentiated Design, Preclinical - GlobeNewswire
First-in-Class Cancer Drug: ALX Oncology's Novel EGFR-ADC Gets FDA Green Light for Clinical Trials - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC - Defense World
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | AL - GuruFocus
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
ALX Oncology To Report First Quarter 2025 Financial Results On May 8, 2025 - Barchart.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Holdings Raised by JPMorgan Chase & Co. - Defense World
Geode Capital Management LLC Raises Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Was Alx Oncology Holdings Inc (ALXO)’s session last reading good? - uspostnews.com
Investor’s Delight: Alx Oncology Holdings Inc (ALXO) Closes Weak at 0.62, Down -4.90 - DWinneX
Alx Oncology Holdings Inc [ALXO] stock was sold by Pinto Shelly at the price of US$633.0 - knoxdaily.com
UBS Adjusts Price Target for ALX Oncology (ALXO) After Trial Out - GuruFocus
UBS Adjusts ALX Oncology Price Target to $1.20 From $2.20, Maintains Buy Rating - marketscreener.com
Market Momentum Report: Alx Oncology Holdings Inc (ALXO)’s Negative Close at 0.54 - DWinneX
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials - Yahoo
ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia
ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):